# A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health

> **NCT02926430** · PHASE1 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 73 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Ad26.RSV.preF 5*10^10 vp
- **BIOLOGICAL:** Ad26.RSV.preF 1*10^11 vp
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02926430
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-08
- **Primary completion:** 2018-03-14
- **Final completion:** 2019-01-29
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2019-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02926430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02926430, "A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02926430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*